Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
NCT00326469
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Neuroendocrine Tumours
Interventions
DRUG:
lanreotide (Autogel formulation)
Sponsor
Ipsen